Provide information or materials on the three medications approved by the Food and Drug Administration to treat opioid use disorder.
Provides guidance on the use of buprenorphine among a number of topics, including physiology and pharmacology of opioids, opioid addiction, and buprenorphine treatment; screening and assessment of OUDs; protocols for buprenorphine treatment; management of special populations; and policies and procedures related to DATA 2000.
Provides guidelines related to opioid dependence that aim to: reduce global barriers to effective treatment; contribute to the development of evidence-based, ethical treatment policies; contribute to improvement of the quality of pharmacological treatment; and facilitate implementation of effective treatment policies and programs.
Provides information on evidence-based treatment of OUD. This guideline is the only document of its kind to include all Food and Drug Administration (FDA)-approved medications in one place.
Offers guidelines for MAT for individuals, particularly veterans, with PTSD and co-occurring OUDs. Covers screening, concomitant treatment, pharmacotherapy, and multiple substances of abuse.
Provides an overview of the key points of the National Practice Guideline, detailed recommendations for OUD diagnosis, and information on treatment settings and opioid withdrawal. Describes MAT options and considerations for treating special populations. Links to additional resources, such as a pocket guide and a slide deck.
Offers guidance on the use of MAT with extended-release injectable naltrexone for the treatment of OUD. Covers assessing patients, initiating MAT, monitoring progress, and deciding when to end treatment.
Reviews three FDA-approved medications for OUD treatment (methadone, naltrexone, and buprenorphine) and the other strategies and services needed to support people in recovery.
Offers clinicians information on medications for opioid addiction treatment, including side effects, drug interactions, and take-home doses. Discusses patient counseling, associated medical problems, hepatitis C evaluation, drug testing, and pregnant women.
Gives an overview of data on the use of sublingual and transmucosal buprenorphine for MAT of OUD. Discusses the implications of using MAT in recovery support.
Email Updates